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effectiveness of screening the general population for elevated albuminuria. The aim of 
this study was to estimate the cost-effectiveness of various ‘screen-and-treat’ scenarios. 
METHODS: A multi-state Markov model was developed to simulate ‘natural course’ 
albuminuria-based progression to dialysis and occurrence of CV-events. Transition 
probabilities were derived from data of the PREVEND study, an observational, 
general population-based cohort study. In the base-case analysis, cost-effectiveness 
was estimated for screening the general population on microalbuminuria (pre-screen-
ing on ﬁrst morning void urinary albumin concentration q20 mg/L and conﬁrmation 
in two 24-hr urine samples with urinary albumin excretion q30 mg). Cost of screening 
and ACE-inhibitor treatment minus savings on dialysis and CV-events was divided by 
life-years gained (LYG) over a 8-years time-horizon, to render the cost-effectiveness 
ratio for the base-case microalbuminuria screening and alternative scenarios. Costs 
(2008 values) and effects were discounted at 4% and 1.5%, respectively. RESULTS: 
Among 1000 subjects identiﬁed with microalbuminuria, 76 versus 124 CV-events, 16 
versus 27 CV-deaths and 3 versus 5 dialysis cases were found for simulating screening 
and treatment versus no screening, respectively. The per-person cost of screening was 
calculated at a926 (a2,003 versus a1,077) and prevention of CV-deaths was estimated 
to gain 0.0421 per-person discounted life years, resulting in a cost-effectiveness of 
a22,000 per LYG. The probability of accepting screening for microalbuminuria with 
maximum willingness-to-pay thresholds of a20,000, a50,000, and a80,000 per LYG, 
was estimated at 54%, 90% and 95%, respectively. Limiting screening to subjects 
aged 50 or 60 even improved cost-effectiveness. Incremental analyses suggest a most 
optimal cost-effectiveness of screening for microalbuminuria. CONCLUSIONS: Our 
current analyses suggest most favorable cost-effectiveness of screening for microalbu-
minuria if compared with other evaluated alternative albuminuria-based scenarios.
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OBJECTIVES: Extended prophylaxis with a low molecular weight heparin (LMWH)         
such as enoxaparin in high risk surgical patients is consistent with the recommendations 
made by the American College of Chest Physicians 8th Conference on Antithrombotic 
and Thrombolytic Therapy. The objective of this study was to compare the costs and 
effectiveness of extended versus non-extended prophylaxis from the perspective of 
Australian public hospitals. METHODS: A decision-analytic model was constructed 
using local treatment algorithms and populated with clinical trial data. A hypothetical 
cohort of 1000 high-risk general surgery patients received enoxaparin 40 mg daily for 
7 days (non-extended prophylaxis) or enoxaparin 40 mg daily for 28 days (extended 
prophylaxis) in an Australian public hospital. Efﬁcacy data were drawn from the 
ENOXACAN II trial (Bergqvist et al, 2002). The modelled simulation estimated the 
incidence of VTE (symptomatic deep vein thrombosis [DVT] and pulmonary embolism 
[PE]) and adverse events (heparin-induced thrombocytopenia [HIT], post-thrombotic 
syndrome [PTS], prophylaxis and treatment-related bleeding, mortality) within 28 
days and one year of initiating prophylaxis. RESULTS: By extending prophylaxis with    
enoxaparin from 7 days to 28 days in 1000 patients, the model estimated 20 fewer 
symptomatic DVTs, 4 fewer symptomatic PEs, 3 fewer deaths, 10 fewer episodes of 
PTS and 140 fewer hospital days. Extending prophylaxis was associated with cost 
savings of $126,242 from the perspective of an Australian public hospital. CONCLU-
SIONS: Extended prophylaxis with enoxaparin 40 mg represents a cost-effective         
treatment option for high-risk general surgery patients in Australia.
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OBJECTIVES: Deep vein thrombosis (DVT) is associated with a high degree of mor-
bidity and requires rapid diagnosis and effective anticoagulant treatment. An accurate 
diagnosis of DVT requires clinical assessment e.g. calculation of pretest-probability 
score (PTP) and objective testing, because the clinical features are non-speciﬁc           
and commonly used imaging techniques can be inconclusive. The use of D-dimer 
assays improves diagnostic accuracy. The aim of this study was to examine the cost-
effectiveness of three different D-dimer assays in the diagnosis of DVT, alone or in 
combination with PTP. METHODS: We construct two decision-analytic models 
(DAM) involving 96 outpatients with clinically suspected acute DVT. First DAM 
involve 96 outpatients and estimate the number needed to screen to ﬁnd one true 
positive patients (NNSTPP) selected for compression ultrasound (CUS) and costs of 
three strategies: DVT screening with D-dimer Plus assay; DVT screening with D-dimer 
Hemosil assay and DVT screening with Vidas D-dimer Exclusion assay. Second DAM 
involves 79 patients selected from the 96 patients according to PTP scoring and esti-
mate NNSTPP and costs of three strategies as for previous model. The cost of strategies 
was calculated on the basis of the consumed resources for diagnostic tests, laboratory 
time and consumables. RESULTS: The perspective of incremental cost-effectiveness 
analysis is the clinical laboratory setting. A diagnostic strategy employing DVT screen-
ing with Vidas D-dimer Exclusion assay had lowest cost per additionally successfully 
diagnosed patient than the strategy employing DVT screening with D-dimer Hemosil 
assay in the ﬁrst DAM (a1.13 vs. 19.15) and second DAM (a8.7 vs. 20.9). CONCLU-
SIONS: In the clinical laboratory setting is sufﬁcient to determine D-dimer concentra-
tion with Vidas D-dimer Exclusion assay for DVT screening. A diagnostic strategy 
using PTP assessment and Vidas D-dimer Exclusion assay effectively diagnoses DVT, 
but expands costs per additionally successfully diagnosed patient.
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OBJECTIVES: To conduct a cost-effectiveness analysis (societal perspective) compar-
ing standard anticoagulation care to genetic testing of cytochrome P450 (CYP2C9) 
and vitamin K epoxide reductase complex subunit 1 (VKORC1) to guide short-term 
warfarin therapy among patients with venous thromboembolism (VTE). METHODS: 
A decision model evaluated use of genotype testing to guide initial dosing during 6-
months of warfarin therapy among VTE patients. The clinical and economic outcomes 
were associated with four alternatives: 1) CYP2C9 and VKORC1 genotype; 2) 
CYP2C9 genotype; 3) VKORC1 genotype; and 4) no testing. All clinical probabilities 
were derived from current scientiﬁc literature. Direct-medical and -nonmedical costs, 
and indirect costs were estimated from published databases and literature. Effective-
ness was measured in quality-adjusted life-years (QALYs) at a discounted rate of 3%. 
All costs were in 2007 U.S. dollars. RESULTS: In the base case analysis, the genotype-
guided dosing strategies demonstrated better health outcomes. Assuming a baseline 
prevalence of CYP2C9 associated warfarin sensitivity of 36% and of VKORC1 
 sensitivity of 63%, the marginal cost-effectiveness of the combination of CYP2C9 
and VKORC1 genotype-guided dosing exceeded $100,000/QALY compared with 
VKORC1 testing alone. However, compared with no testing, the cost-effectiveness of 
testing decreased to $0,000/QALY. At a threshold of $100,000/QALY the probabil-
ity for CYP2C9 and VKORC1 genotype-guided dosing to likely be cost-effective 
was 70%.Overall, the cost-effectiveness analysis demonstrated VKORC1 genotype-
guided dosing to be the optimal strategy (probability  0.64). Sensitivity analysis 
showed that for CYP2C9 and VKORC1 genotype-guided dosing to cost less than 
$100,000/QALY it would have to cost less than $440/test or be restricted to patients 
with high risk of bleed given an INR increase (RR  3.9–5.8). CONCLUSIONS: In 
the general population, VKORC1 is cost-effective. However, restricting the testing to 
patients at high risk of bleed, a combination of both genotype-guided dosing is most 
likely to be cost-effective compared with the standard care.
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OBJECTIVES: To evaluate the short-term cost-effectiveness of achieving multiple 
optimal lipid values (MOLV) for fenoﬁbric acid (FFA) co-administered with low- 
cost generic simvastatin (20 mg and 40 mg) compared to co-administration with 
branded rosuvastatin (10 mg and 20 mg) or atorvastatin (20 mg and 40 mg) in post-
menopausal female, elderly (age q 65 years), metabolic syndrome, and diabetic patient       
subgroups with mixed dyslipidemia. METHODS: A disease outcomes model was used 
to estimate MOLV attainment (achieving any 3 of 4 targets: total-C  200 mg/dL, 
LDL-C  130 mg/dL, HDL-C  40 mg/dL or 50 mg/dL pending subgroup, TG  
150 mg/dL) and associated annual drug costs for patients receiving FFA and a statin. 
Subgroup-speciﬁc baseline lipid values, lipid efﬁcacy, and adherence rates were 
obtained from pooled analyses of three 12-week, double-blind, randomized controlled 
trials of FFA co-administered with a statin. FFA and statin costs were based on 
wholesale acquisition costs net of patient copayments. RESULTS: The predicted pro-
portion of patients achieving MOLV for FFA co-administered with moderate-dose 
simvastatin, rosuvastatin, and atorvastatin ranged from 39%–68%, 56%–90%, and 
50%–80%, respectively, across the four patient subgroups. Corresponding per patient 
drug costs ranged from $859–$886, $1730–$1822, and $1718–1896, respectively, 
and per patient costs to achieve MOLV ranged from $1281–$2266, $1926–$3195, 
and $2299–$3415, respectively. The incremental cost effectiveness ratio (ICER) for 
one additional patient achieving MOLV for FFA co-administered with moderate-dose 
rosuvastatin or atorvastatin versus generic simvastatin was $6,376 and $20,552 in 
post-menopausal female; $3,937 and $7,926 in elderly; $5,272 and $8,869 in meta-
bolic syndrome; and $5,412 and $7,426 in diabetic patient subgroups, respectively. 
For low-dose statin combinations, qualitative results were similar though ICERs 
were higher in the elderly and diabetic patient subgroups. CONCLUSIONS: Co-
administration of FFA with low-cost generic simvastatin results in slightly fewer 
patients achieving MOLV but has the lowest annualized cost per MOLV achieved 
compared to equivalent dose combinations with rosuvastatin or atorvastatin in special 
populations.
